{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:54:35Z","timestamp":1781636075940,"version":"3.54.5"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"\u010cesk\u00e1 kardiologick\u00e1 spole\u010dnost","award":["\u010cesk\u00e1 kardiologick\u00e1 spole\u010dnost"],"award-info":[{"award-number":["\u010cesk\u00e1 kardiologick\u00e1 spole\u010dnost"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and aim of the study<\/jats:title>\n                    <jats:p>Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA) is an increasingly recognized disease in elderly individuals. We aimed to perform a cross-sectional survey investigating the current diagnostic journey of ATTRwt patients in the Czech Republic from initial symptoms to final diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Between November 2022 and May 2023, most data were prospectively obtained using a dedicated questionnaire from 118 ATTRwt-CA patients during the regular outpatient consultation. The rest of the data were taken by attending physicians from medical records.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean age of the patients at the time of diagnosis was 77\u2009\u00b1\u20096 years, 85.6% were males. The time interval from the onset of clinical scenario leading to suspicion of CA to suspected diagnosis was 14\u00b124 months, while the subsequent period to definite ATTRwt-CA diagnosis was 2.5\u00b12.3 months. Heart failure primarily led to the suspicion of CA in 61.9%, followed by suspicious echocardiographic findings (12.7%) and atrial fibrillation or flutter (6.8%). The history of carpal tunnel syndrome was the most common extracardiac manifestation found in 53.9% subjects, with median duration of 99 months. The diagnosis of CA was most often first suspected by outpatient cardiologists (33.1%) and cardiologists working at a cardiocenter (25.4%). At the time of diagnosis, NYHA class I or II was present in 10% and 56% of patients, respectively. The definite ATTRwt-CA diagnosis was made noninvasively in 63% cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A relatively long-time delay still exists between the onset of clinical manifestations and suspicion of CA. Nevertheless, once CA is suspected, the definite ATTRwt-CA diagnosis is made early. Although heart failure still represents the most common clinical scenario, several other clinical profiles lead quite frequently to suspicion of the disease. The non-invasive diagnostics of ATTRwt-CA is done in majority of our patients, who are diagnosed mostly in early stages of the disease. The awareness of ATTRwt manifestations must be increased in order to shorten the whole diagnostic process of the disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04249-x","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T07:03:19Z","timestamp":1770966199000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Wild-type transthyretin cardiac amyloidosis: the journey to diagnosis in the Czech Republic"],"prefix":"10.1186","volume":"21","author":[{"given":"Barbora","family":"Chocholova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Weislova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Poloczkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eniko","family":"Marczibal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Aiglova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milos","family":"Kubanek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Krejci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Palecek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"issue":"1","key":"4249_CR1","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","volume":"142","author":"MM Kittleson","year":"2020","unstructured":"Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology, et al. Cardiac amyloidosis: evolving diagnosis and management: A scientific statement from the American heart association. Circulation. 2020;142(1):e7\u201322. https:\/\/doi.org\/10.1161\/CIR.0000000000000792.","journal-title":"Circulation"},{"key":"4249_CR2","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/eurheartj\/ehae811","volume":"46","author":"E Gonzalez-Lopez","year":"2025","unstructured":"Gonzalez-Lopez E, Maurer MS, Garcia-Pavia P. Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine. Eur Heart J. 2025;46:999\u20131013. https:\/\/doi.org\/10.1093\/eurheartj\/ehae811.","journal-title":"Eur Heart J"},{"issue":"8","key":"4249_CR3","doi-asserted-by":"publisher","first-page":"e012112","DOI":"10.1161\/CIRCHEARTFAILURE.124.012112","volume":"18","author":"M Fontana","year":"2025","unstructured":"Fontana M, Berk JL, Drachman B, Garcia-Pavia P, Hanna M, Lairez O, et al. Changing treatment landscape in transthyretin cardiac amyloidosis. Circ Heart Fail. 2025;18(8):e012112. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.124.012112.","journal-title":"Circ Heart Fail"},{"key":"4249_CR4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","volume":"140","author":"T Lane","year":"2019","unstructured":"Lane T, Fontana M, Martinez-Naharro A, Quarta CC, Whelan CJ, Petrie A, et al. Natural History, quality of Life, and outcome in cardiac transthyretin amyloidosis. Circulation. 2019;140:16\u201326. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.038169.","journal-title":"Circulation"},{"key":"4249_CR5","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ijcard.2019.12.063","volume":"304","author":"B Ladefoged","year":"2020","unstructured":"Ladefoged B, Dybro A, Povlsen JA, Vase H, Clemmensen TS, Poulsen SH. Diagnostic delay in wild type transthyretin cardiac amyloidosis - A clinical challenge. Int J Cardiol. 2020;304:138\u201343. https:\/\/doi.org\/10.1016\/j.ijcard.2019.12.063.","journal-title":"Int J Cardiol"},{"key":"4249_CR6","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ejhf.2140","volume":"23","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European society of cardiology working group on myocardial and pericardial diseases. Eur J Heart Fail. 2021;23:512\u201326. https:\/\/doi.org\/10.1002\/ejhf.2140.","journal-title":"Eur J Heart Fail"},{"key":"4249_CR7","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1002\/ehf2.12793","volume":"7","author":"D Dang","year":"2020","unstructured":"Dang D, Fournier P, Cariou E, Huart A, Ribes D, Cintas P, et al. Gateway and journey of patients with cardiac amyloidosis. ESC Heart Fail. 2020;7:2418\u201330. https:\/\/doi.org\/10.1002\/ehf2.12793.","journal-title":"ESC Heart Fail"},{"key":"4249_CR8","doi-asserted-by":"publisher","first-page":"e0297182","DOI":"10.1371\/journal.pone.0297182","volume":"19","author":"SM Ihne-Schubert","year":"2024","unstructured":"Ihne-Schubert SM, Leberzammer M, Weidgans M, Frantz S, Einsele H, Knop S, et al. Single German centre experience with patient journey and care-relevant needs in amyloidosis: the German AMY-NEEDS research and care program. PLoS ONE. 2024;19:e0297182. https:\/\/doi.org\/10.1371\/journal.pone.0297182.","journal-title":"PLoS ONE"},{"key":"4249_CR9","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/13506129.2022.2035354","volume":"29","author":"T Damy","year":"2022","unstructured":"Damy T, Adams D, Bridoux F, Grateau G, Plant\u00e9-Bordeneuve V, Ghiron Y, et al. Amyloidosis from the patient perspective: the French daily impact of amyloidosis study. Amyloid. 2022;29:165\u201374. https:\/\/doi.org\/10.1080\/13506129.2022.2035354.","journal-title":"Amyloid"},{"key":"4249_CR10","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/ejhf.2823","volume":"25","author":"G Tini","year":"2023","unstructured":"Tini G, Milani P, Zampieri M, Caponetti AG, Fabris F, Foli A, et al. Diagnostic pathways to wild-type transthyretin amyloid cardiomyopathy: a multicentre network study. Eur J Heart Fail. 2023;25:845\u201353. https:\/\/doi.org\/10.1002\/ejhf.2823.","journal-title":"Eur J Heart Fail"},{"key":"4249_CR11","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/eurheartj\/ehx043","volume":"38","author":"E Gonz\u00e1lez-L\u00f3pez","year":"2017","unstructured":"Gonz\u00e1lez-L\u00f3pez E, Gagliardi C, Dominguez F, Quarta CC, de Haro-Del Moral FJ, Milandri A, et al. Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving Myths. Eur Heart J. 2017;38:1895\u2013904. https:\/\/doi.org\/10.1093\/eurheartj\/ehx043.","journal-title":"Eur Heart J"},{"key":"4249_CR12","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.rec.2019.12.020","volume":"74","author":"\u00c1 L\u00f3pez-Sainz","year":"2021","unstructured":"L\u00f3pez-Sainz \u00c1, Hernandez-Hernandez A, Gonzalez-Lopez E, Dom\u00ednguez F, Restrepo-Cordoba MA, et al. Clinical profile and outcome of cardiac amyloidosis in a Spanish referral center. Rev Esp Cardiol. 2021;74:149\u201358. https:\/\/doi.org\/10.1016\/j.rec.2019.12.020.","journal-title":"Rev Esp Cardiol"},{"key":"4249_CR13","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1186\/s13023-024-03407-3","volume":"19","author":"C Karam","year":"2024","unstructured":"Karam C, Moffit C, Summers C, Merkel MP, Kochman FM, Weijers L, et al. The journey to diagnosis of wild-type transthyretin-mediated (ATTRwt) amyloidosis: a path with multisystem involvement. Orphanet J Rare Dis. 2024;19:419. https:\/\/doi.org\/10.1186\/s13023-024-03407-3.","journal-title":"Orphanet J Rare Dis"},{"key":"4249_CR14","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1093\/ehjci\/jeaa063","volume":"21","author":"R Jurcu\u0163","year":"2020","unstructured":"Jurcu\u0163 R, Onciul S, Adam R, Stan C, Coriu D, Rapezzi C, et al. Multimodality imaging in cardiac amyloidosis: a primer for cardiologists. Eur Heart J Cardiovasc Imaging. 2020;21:833\u201344. https:\/\/doi.org\/10.1093\/ehjci\/jeaa063.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"4249_CR15","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.1002\/ehf2.14971","volume":"11","author":"P Garcia-Pavia","year":"2024","unstructured":"Garcia-Pavia P, Damy T, Piriou N, Barriales-Villa R, Cappelli F, Bahus C, et al. Prevalence and characteristics of transthyretin amyloid cardiomyopathy in hypertrophic cardiomyopathy. ESC Heart Fail. 2024;11:4314\u201324. https:\/\/doi.org\/10.1002\/ehf2.14971.","journal-title":"ESC Heart Fail"},{"key":"4249_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12891-020-03912-z","volume":"22","author":"AE Wininger","year":"2021","unstructured":"Wininger AE, Phelps BM, Le JT, Harris JD, Trachtenberg BH, Liberman SR. Musculoskeletal pathology as an early warning sign of systemic amyloidosis: a systematic review of amyloid deposition and orthopedic surgery. BMC Musculoskelet Disord. 2021;22:51. https:\/\/doi.org\/10.1186\/s12891-020-03912-z.","journal-title":"BMC Musculoskelet Disord"},{"key":"4249_CR17","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","volume":"39","author":"JD Gillmore","year":"2017","unstructured":"Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2017;39:2799\u2013806. https:\/\/doi.org\/10.1093\/eurheartj\/ehx589.","journal-title":"Eur Heart J"},{"key":"4249_CR18","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379:1007\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1805689.","journal-title":"N Engl J Med"},{"key":"4249_CR19","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jacc.2018.03.536","volume":"70","author":"A Martinez-Naharro","year":"2017","unstructured":"Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Zumbo G, Knight DS, et al. Magnetic resonance in transthyretin cardiac amyloidosis. J Am Coll Cardiol. 2017;70:466\u201377. https:\/\/doi.org\/10.1016\/j.jacc.2018.03.536.","journal-title":"J Am Coll Cardiol"},{"key":"4249_CR20","first-page":"102","volume":"12","author":"M Magdi","year":"2022","unstructured":"Magdi M, Mostafa MR, Abusnina W, Al-Abdouh A, Doss R, Mohamed S, et al. A systematic review and meta-analysis of the prevalence of transthyretin amyloidosis in heart failure with preserved ejection fraction. Am J Cardiovasc Dis. 2022;12:102\u201311.","journal-title":"Am J Cardiovasc Dis"},{"key":"4249_CR21","doi-asserted-by":"publisher","first-page":"2418965","DOI":"10.1080\/07853890.2024.2418965","volume":"56","author":"A Achten","year":"2024","unstructured":"Achten A, Muller SA, Wijk SS, van der Meer MG, van der Harst P, et al. Diversity of heart failure phenotypes in transthyretin amyloid cardiomyopathy. More than just heart failure with preserved ejection fraction. Ann Med. 2024;56:2418965. https:\/\/doi.org\/10.1080\/07853890.2024.2418965.","journal-title":"Ann Med"},{"key":"4249_CR22","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.amjcard.2020.05.021","volume":"128","author":"E Donnellan","year":"2020","unstructured":"Donnellan E, Wazni OM, Saliba WI, Hanna M, Kanj M, Patel DR, et al. Prevalence, Incidence, and impact on mortality of conduction system disease in transthyretin cardiac amyloidosis. Am J Cardiol. 2020;128:140\u20136. https:\/\/doi.org\/10.1016\/j.amjcard.2020.05.021.","journal-title":"Am J Cardiol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04249-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04249-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04249-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:13:04Z","timestamp":1781633584000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04249-x"}},"subtitle":["The research project of the Czech Society of Cardiology"],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4249"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04249-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7950257\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"B.C.: honoraria for lectures (Pfizer), support for attending meetings (Pfizer). I.W.: none. H.P.: honoraria for lectures (Pfizer), support for attending meetings (Pfizer), advisory board (Bayer). E.M.: none. R.A.: honoraria for lectures (Pfizer, Bayer), support for attending meetings (Pfizer), advisory boards (Pfizer, Bayer, Medison Pharma). M.K.: honoraria for lectures (Pfizer), support for attending meetings (Pfizer), advisory boards (Pfizer, Bayer, Medison Pharma). J.K.: honoraria for lectures (Pfizer, Bayer), support for attending meetings (Pfizer), advisory boards (Pfizer, Bayer, Medison Pharma). T.P.: honoraria for lectures (Pfizer, Bayer), support for attending meetings (Pfizer), advisory boards (Pfizer, Bayer, Medison Pharma).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"103"}}